WS #16379
Heineken has formally advised hospitality partners to adapt to rising consumer use of GLP-1 weight-loss medications, which the company notes may reduce demand for beer and cider. This represents a significant structural shift for the beverage industry, potentially impacting long-term volume growth for major brewers and hospitality operators exposed to social drinking environments.
GLP-1 Impact on Beverage and Hospitality
Heineken has formally advised hospitality partners to adapt to rising consumer use of GLP-1 weight-loss medications, which the company notes may reduce demand for beer and cider. This represents a significant structural shift for the beverage industry, potentially impacting long-term volume growth for major brewers and hospitality operators exposed to social drinking environments.